Home/Filings/4/0000899243-21-045070
4//SEC Filing

Kiener Peter A 4

Accession 0000899243-21-045070

CIK 0001645460other

Filed

Nov 16, 7:00 PM ET

Accepted

Nov 17, 5:00 PM ET

Size

15.1 KB

Accession

0000899243-21-045070

Insider Transaction Report

Form 4
Period: 2021-11-15
Transactions
  • Exercise/Conversion

    Common Stock

    2021-11-16$2.86/sh+1,361$3,8921,361 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2021-11-161,361105,744 total
    Exercise: $2.86Exp: 2023-03-23Common Stock (1,361 underlying)
  • Exercise/Conversion

    Common Stock

    2021-11-15$2.86/sh+18,815$53,81118,815 total
  • Sale

    Common Stock

    2021-11-15$17.92/sh18,815$337,1650 total
  • Sale

    Common Stock

    2021-11-16$18.02/sh1,361$24,5250 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2021-11-1518,815107,105 total
    Exercise: $2.86Exp: 2023-03-23Common Stock (18,815 underlying)
Footnotes (4)
  • [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2020.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.86 to $18.20, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.86 to $18.31, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (3) to this Form 4.
  • [F4]The option vests in five equal annual installments beginning March 23, 2017.

Issuer

Cue Biopharma, Inc.

CIK 0001645460

Entity typeother

Related Parties

1
  • filerCIK 0001328146

Filing Metadata

Form type
4
Filed
Nov 16, 7:00 PM ET
Accepted
Nov 17, 5:00 PM ET
Size
15.1 KB